44
https://pubmed.ncbi.nlm.nih.gov/38091293
Researchers have designed potent and specific proteasome inhibitors targeting β2, based on the structure of the endogenous inhibitor PI31/Fub1, which may provide a new treatment approach for multiple myeloma and enhance existing therapies.
